China's iKang Healthcare wants to go private in a management-led $1.1 billion offer that would see it delist from the U.S., making it among a handful of healthcare-related companies from the Middle Kingdom to pursue that strategy this year.
Japan's Ministry of Health, Labor and Welfare wants more funds next budget year to pursue innovative drug and medical device development as it also struggles with growing healthcare costs in part brought on by a weaker yen that has made imports more expensive.
Infusion pumps are one of the more problematic categories of medical devices with myriad adverse events, including deaths, and recalls associated with the devices. Ivenix expects that its next-gen infusion management system could improve patient safety and workflow efficiency--as well as to adhere to more stringent FDA guidance on infusion systems issued in December.
NovoCure has filed for an IPO to raise up to $300 million on the strength of a potential FDA approval for its Optune device in combination with chemotherapy for patients with newly diagnosed glioblastoma.
Swiss diabetes device maker CeQur roped in $100 million in a Series C round for its patchlike insulin infusion device, helping the company ramp up operations and launch its product next year.
Germany's coramaze technologies announced that it is receiving €4.5 million ($5.05 million) in a Series A round led by Israel's Elron Electronic Industries, making it the latest player in the burgeoning field of transcatheter mitral valve devices.
A key drug company in China fired a new salvo in the online over-the-counter healthcare market with an eye on wider sales of ethical products in hopes the China Food and Drug Administration (CFDA) will come through on plans to allow online sales of prescription drugs at some point this year.
Private equity group Essex Woodlands has snapped up a 16% stake in surgical peripheral nerve solutions company AxoGen. The company raised $17.5 million to back its existing regenerative medicine products, as well as to develop new candidates for nerves severed during prostate cancer surgery and lower extremity nerve injuries. The financing is expected to put the company in the black for the first time.
Shares of Patterson Companies were down more than 7% to $45.53 on Thursday morning, after the distributor announced disappointing results for its fiscal first quarter. The company reported sales of $1.1 billion and earnings of $46.9 million, or $0.47 a share. Even though earnings were up more than 17% year-over-year, analysts had been expecting EPS of $0.54 on sales of $1.8 billion.
Israeli Viola Private Equity will invest up to $28.4 million in an Israeli publicly listed micro-cap medical device company Itamar Medical. The investment will make the firm the largest shareholder in the cardiovascular and sleep apnea specialist.